Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Trump Says He Will Allow States to Import Prescription Drugs to Lower Costs

Reuters Staff  |  November 25, 2019

WASHINGTON (Reuters)—U.S. President Donald Trump said on Friday, Nov. 22, he will soon release a plan to let Florida and other states import prescription medicines to combat high drug prices. He blasted the Democrat-led U.S. House of Representatives for not going far enough in a drug-pricing bill. “We will soon be putting more options on…

New Consensus Recommendations Guide Sjögren’s Syndrome Management

Will Boggs, MD  |  November 25, 2019

NEW YORK (Reuters Health)—New consensus-based recommendations from the European League Against Rheumatism (EULAR) address the management of Sjögren’s syndrome with topical and systemic therapies. Sjögren’s syndrome presents with a broad spectrum of clinical manifestations and autoantibodies, including antinuclear antibodies (the most frequently detected), anti-Ro/SS-A (the most specific) and cryoglobulins and hypocomplementemia (the main prognostic markers)….

Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

Michele B. Kaufman, PharmD, BCGP  |  November 25, 2019

Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…

3 Tips for Financial Discussions with Patients

Carina Stanton  |  November 25, 2019

Issues related to the costs and insurance coverage associated with rheumatologic care can be complex and overwhelming for patients. Here’s how one private practice addresses the financial side of treatment with its patients…

Renal Transplant Outcomes in Patients with Lupus Nephritis

Lara C. Pullen, PhD  |  November 25, 2019

A recent study from Brazil suggests lupus nephritis patients who receive renal transplant have a high five-year survival rate. Researchers found the presence of venous thrombosis and antiphospholipid syndrome, but not viral infection, were important predictors of renal graft loss in these patients…

ACR Supports Bill to Establish Minimum DXA Payment

From the College  |  November 21, 2019

Legislation introduced in both houses of Congress would set a minimum Medicare reimbursement of $98 for DXA bone density scans.

Sindhu Johnson, MD, PhD, FRCPC, to Head the Committee on Quality of Care

Kelly Tyrrell  |  November 21, 2019

Sindhu Johnson, MD, PhD, FRCPC, has co-chaired the classification and response criteria subcommittee and brings extensive experience in classification and guideline development to her new role.

ACR Leverages AMA Representation to Advance Rheumatology Issues

Adam Cooper  |  November 21, 2019

The ACR’s delegation to the AMA HOD meeting in November successfully advanced resolutions to advocate for pharmacy benefit manager transparency and expanded patient protections from step therapy protocols.

Progress on Preventing Immune-Related Adverse Events

Mike Fillon  |  November 20, 2019

ATLANTA—One of the hottest topics in medicine is the emerging field of cancer immunotherapy. However, immune-related adverse events (irAEs) are associated with the therapy, and when things go wrong, they can go very, very wrong, said Ryan Sullivan, MD, during the 2019 ACR/ARP Annual Meeting in November. “The guiding principle of cancer immunotherapy is [that]…

Collegiality—an ARP Mainstay

Thomas R. Collins  |  November 20, 2019

ATLANTA—In the late 1990s, at the Annual Meeting, a colleague asked Marian Hannan, DSc, MSc, who is now professor of medicine at Harvard Medical School, if she wanted to go to a tourist attraction and talk about professional pursuits during a break at the conference. The colleague ranked higher than she did, and she didn’t…

  • « Previous Page
  • 1
  • …
  • 229
  • 230
  • 231
  • 232
  • 233
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences